Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this efficacy appears enhanced in combination with conven...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2017
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395112/
https://ncbi.nlm.nih.gov/pubmed/28034990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.158394
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items